NPPA and Parkinson disease: We recently demonstrated that ANP affects the Wnt/β-catenin pathway possibly through an Fzd receptor-mediated mechanism [53, 54], and that it acts as a neuroprotective agent in in vitro models of PD by upregulating this signaling [55].